Анемия на фоне химиотерапии. Пути коррекции
- Авторы: Абрамов М.Е.1
-
Учреждения:
- ФГБУ “Онкологический научный центр им. Н.Н. Блохина" РАМН
- Выпуск: № 8 (2012)
- Страницы: 51-55
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/279562
- ID: 279562
Цитировать
Полный текст
Открытый доступ
Доступ предоставлен
Доступ платный или только для подписчиков
Аннотация
Наиболее частым осложнением химиотерапии является анемия. Гемотрансфузии используются, когда необходимо быстро повысить уровень гемоглобина. Широкое применение эритропоэтинов с целью лечения анемии у онкологических больных позволило значительно снизить количество гемотрансфузий и, соответственно, связанные с ними риски. У пациентов со злокачественными новообразованиями часто развивается дефицит железа. Эффективность терапии эритропоэтинами значительно увеличивается при использовании внутривенных препаратов железа. С целью коррекции дефицита железа в настоящее время широко используется высокоэффективный препарат для внутривенного введения Феринжект®, возможности применения которого при анемии на фоне химиотерапии рассматриваются.
Ключевые слова
Полный текст
Об авторах
Михаил Евгеньевич Абрамов
ФГБУ “Онкологический научный центр им. Н.Н. Блохина" РАМН
Email: mikhailabramov@newmail.ru
кандидат медицинских наук, старший научный сотрудник отделения комбинированных методов лечения и химиотерапии злокачественных опухолей Москва
Список литературы
- Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-306.
- Schrijvers D, De Samblanx H, Roila F. On behalf of the ESMO Guidelines Working Group* Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. 2012.
- Steensma DP. Is anaemia of cancer different from chemotherapy-induced anaemia? J Clin Oncol 2008;26:1022-24.
- Павлов А.Д, Морщакова Е.Ф., Румянцев А.Г. Анемия при злокачественных новообразованиях: патогенез и лечение рекомбинантным человеческим эритропоэтином // Современная онкология 2002. № 4. С. 50-54.
- Groopman J, Itri L. Chemotherapy-induced anemia in adults: incidence and treatment. J Nat Cancer Inst 1999;91:1616-34.
- NCCN clinical practice guidelines. Cancer- and chemotherapy-induced anemia. V2 2010. Available at http://www.nccn.org/professionals /physician_gls/PDF/anemia.pdf.
- Stasi R, Abriani L, Beccaglia P, et al. Cancer-related fatigue: evolving concepts in evaluation and treatmen. Cancer 2003;98:1786-801.
- NCCN clinical practice guidelines. Cancer- and chemotherapy-induced anemia. V2 2012.
- Kader A, Lim J, Berthelet E, et al. Prognostic significance of blood transfusions in patients with esophageal cancer treated with combined chemoradiotherapy. Am J Clin Oncol 2007;30:492-97.
- Williamson LM, Lowe S, Love EM, et al. Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports. BMJ 1999;319:16-19.
- Khorana A, Francis C, Blumberg N, et al. Blood transfusions, thrombosis and mortality in hospitalized patients with cancer. Arch Intern Med 2008;168:2377-81.
- Littlewood TJ, Baretta E, Nortier JW, et al. Effects of erythropoietin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: results of a randomised, double-blind, placebo controlled trial. J Clin Oncol 2001;19:2865-24.
- Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo controlled, randomised phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2001;94:1211-20.
- Bohlius J, Wilson J, Seiden feld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-14.
- Buck I, Morceau F, Cristofanon S, et al. Linking anemia to inflammation and cancer: the crucial role of TNFa. Biochem Pharmacol 2009. [epub ahead of print], doi: 10.1016/j. bcp.2008.12.018.
- Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal haemoglobin levels with epoetin alfa in mainly non-anemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-72.
- FDA press release: FDA receives new data on risks of anemia drugs consistent with previous data on tumor growth and death. http:// www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2008/ucm116830.htm
- Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoietin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-24.
- Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoietin-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532-42.
- Tonelli M, Hemmelgarn B, Reiman T, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta analysis. CMAJ 2009;180:E62-E71.
- Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010; 102:1-35.
- Ludwig H, Crawford J, Osterborg A, et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009;27:2838-47.
- Glaspy J, Osterborg A, Ludwig H, et al. Evaluation of the association between (Hb) events and safety outcomes in cancer patients with chemotherapy induced anemia: an integrated analysis of patient-level data from 6 randomized, placebo-controlled trials of darbepoetin. Eur J Cancer Suppl 2007:5. 24.2007 Oncologic Drug Advisory Committee (ODAC) Meeting Information Package. Darbepoetin alfa (BLA # 103951) and Epoetin alfa (BLA # 103234). 53. 54. Available at http://www.scribd.com/doc/1117102/ US-Food-and-Drug-Administration-20074301b20101Amgen
- Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-307.
- Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231-42.
- Auerbach M, Silberstein P, Webb R, et al. Darbepoietin alfa 500 mcg or 300 mcg once every three weeks with or without iron in patients with chemotherapy-induced anemia. Am J Hematol 2010;85(9):655-63.
- Henry DH, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231-42.
- Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 2008;26(10):1611-18.
- Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 2010;116(3):522-25.
Дополнительные файлы
